查看文章

Objective:

The Simplification of antiretroviral therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine trial (STEAL) study randomized HIV participants to switch existing nucleoside reverse transcriptase inhibitors (NRTI) to either abacavir/lamivudine (ABC/3TC; n= 179) or tenofovir/emtricitabine (TDF/FTC; n= 178). An increased risk in cardiovascular disease (CVD) was reported (hazard ratio 7.7, P= 0.048) in ABC/3TC recipients compared with TDF/FTC in the STEAL study. The impact of ABC/3TC treatment on a range of CVD and inflammatory biomarkers was explored.

Design and methods:

Biomarkers were assessed at 0, 12, 24, and 48 weeks to examine: inflammation–high sensitive C-reactive protein, amyloid-P, amyloid-A, interleukin 6, interleukin 10, interferon α, and macrophage migration inhibitory factor; coagulation–D-dimer and fibrinogen; platelet function–soluble P-selectin; endothelial function–vascular …